Publications by authors named "S Roze"
Clinical trials and real-world data for Type II diabetes both show that glycated hemoglobin (HbA1c) levels and hypoglycemia occurrence can be reduced by real-time continuous glucose monitoring (rt-CGM) versus self-monitoring of blood glucose (SMBG). The present cost-utility study investigated the long-term health economic outcomes associated with using rt-CGM versus SMBG in people with insulin-treated Type II diabetes in France. Effectiveness data were obtained from a real-world study, which showed rt-CGM reduced HbA1c by 0.
View Article and Find Full Text PDFAims/hypothesis: The aim of this study was to assess the long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring (rtCGM) with alert functionality compared with FreeStyle Libre 1 intermittently scanned continuous glucose monitoring (isCGM) without alerts in adults with type 1 diabetes in Belgium.
Methods: The IQVIA CORE Diabetes Model was used to estimate cost-effectiveness. Input data for the simulated baseline cohort were sourced from the randomised ALERTT1 trial (ClinicalTrials.
Background: To estimate the economic impact of preventing urinary tract infections (UTI) by increasing water intake among women with recurrent UTI and low fluid intake across seven countries: France, United Kingdom, Spain, United States of America, Mexico, China and Australia.
Methods: A Markov model was developed to compare costs and outcomes of UTIs associated with low fluid intake in women versus a strategy of primary prevention by increasing water intake. Model inputs were based on randomized controlled trial data which found that increasing water intake by 1.
Article Synopsis
- Real-time continuous glucose monitoring (rt-CGM) leads to lower glycated hemoglobin (A1c) levels and reduced hypoglycemia compared to self-monitoring of blood glucose (SMBG) for insulin-treated Type 2 diabetes patients.
- An analysis of health and economic outcomes in Canada found that using rt-CGM resulted in higher lifetime costs (CAD 207,466) but also better quality-adjusted life expectancy (9.97 QALYs) compared to SMBG (CAD 189,863 and 9.02 QALYs, respectively).
- The incremental cost-utility ratio (ICUR) for rt-CGM was CAD 18,523 per QALY gained, suggesting that rt-CGM is likely a
Aims: To determine the cost-effectiveness of the Dexcom G6 real-time continuous glucose monitoring (rt-CGM) system compared with both the self-monitoring of blood glucose (SMBG) and the Abbott FreeStyle Libre 1 and 2 intermittently scanned CGM (is-CGM) devices in people with type 1 diabetes receiving multiple daily insulin injections in Denmark.
Materials And Methods: The analysis was performed using the IQVIA Core Diabetes Model, which associates rt-CGM use with glycated haemoglobin reductions of 0.6% and 0.